Expert Interview
Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Ticker(s): LLY, AZN, NVOInstitution: Refuah Health
- Fellowish trained endocrinologist at Refuah Health; Former Chief of Endocrinology at Bronx-Lebanon Hospital Center (2006-2018)
- Authored several research articles and has numerous lectures in the endocrinology space
- Clinical areas of interest include diabetes, prediabetes, obesity, lipid disorders, PCOS, hypogonadism, osteoporosis/osteopenia, and thyroid, adrenal, electrolyte, and pituitary disorders
- Currently treats 2500 patients with type 2 diabetes, prescribes Mounjaro (tirzepatide) to 25 patients; familiar with the published data for Icodec
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
